Our Areas of Interest
In our Pharmaceuticals division we concentrate on the research and development of innovative drugs and novel therapeutic approaches in fields with high medical need. We are also constantly improving our range of established products, building on our experience of more than 150 years in the pharmaceuticals business.
What partnering projects are we looking for?
We look for partnering opportunities in a broad range of fields, from fundamental research to early research projects, drug targets and leads as a basis of new therapeutic approaches, drug candidates in clinical development and marketed products, disease-related biomarkers, software and digital technologies as well as services that can benefit patients and physicians in our major therapeutic fields:
Partnering in Cardiology
In Cardiology, we look for partnering options that can benefit patients in cardiovascular diseases from heart failure, hypertension, heart attack and stroke, atrial fibrillation, acute coronary syndrome (ACS), thrombosis, peripheral arterial occlusive disease, acute lung injury / acute respiratory distress syndrome, cardio-renal syndrome (CRS), pulmonary hypertension and inflammatory and fibrotic lung diseases, to chronic kidney diseases.
To address research in cardiovascular diseases, we focus on targets in the renin-angiotensin-aldosterone system (RAAS), the adenosine receptor system, on nitric oxide and soluble guanylate cyclase (sGC), the regulation of erythropoietin production by HIF-PH, and the blood coagulation cascade as a key point of control for many processes.
Partnering in Hematology
In Hematology, our R&D focus is on innovative targets for hemophilia, rare blood disorders, acute bleeding and hemoglobinopathies.
Partnering in Oncology
In Oncology we look forward to partnering with you on projects that can advance the treatment of cancer and improve the quality of life for cancer patients. Our pipeline addresses various tumor types, including prostate cancer, lung and breast cancer, as well as rare forms like kidney, liver and thyroid cancer.
We invite research collaboration opportunities on projects that counteract the proliferation of cancer cells, that interrupt the cell cycle or survival signaling of the tumor cells, attack the tumor metabolism, counteract cancer stem cells, address epigenetics and chromatin modulation, or activate immunotherapeutic approaches, such as antibody-drug conjugates and checkpoint modulators. Furthermore, we are interested in biomarker projects and approaches to advance personalized medicine in oncology. In addition, we are interested in collaborations on development projects on any kind of solid and liquid tumors.
Partnering in Women’s Healthcare / Gynecological Therapies
In Women’s Healthcare we research and develop new and improved treatment options for a range of gynecological indications. We look forward to partnering with you in the development of novel drugs and treatment approaches for endometriosis (including adenomyosis uteri / endometriosis interna) and uterine fibroids (uterine leiomyoma).
Partnering in Ophthalmology
In Ophthalmology, we are focused on identifying innovative partnering opportunities for retinal disorders to help improve or prevent loss of vision. We look to complement our research and development to benefit patients with exudative retinal diseases such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion and myopic choroidal neovascularization. We are also looking for partnering options to expand our research portfolio to treat non-exudative retinal diseases such as dry age-related macular degeneration, geographic atrophy and Stargardt’s disease.
While committed to complementing this growing back-of-the-eye pipeline, Bayer also targets advanced clinical stage assets with significant innovation in selective front-of-the-eye conditions including glaucoma and dry eye disease.
Partnering in Radiology
In Radiology, we constantly improve our diagnostic imaging offerings and medical equipment to support the diagnosis and treatment of various diseases. We invite projects that can potentially extend or advance our portfolio of contrast agents, contrast injection technologies, software and technologies to enhance radiation and contrast management, as well as other services that benefit radiologists and patients in computed tomography (CT)/X-ray and magnetic resonance imaging (MRI).